TRIM32 Gene

TRIM32 Gene

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">TRIM32 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>TRIM32</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Tripartite Motif Containing 32</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>9q33.1</td>
</tr>
<tr>
<td class="label">Protein Type</td>
<td>E3 Ubiquitin Ligase</td>
</tr>
<tr>
<td class="label">Protein Size</td>
<td>653 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~72 kDa</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>TEB4, HTRE2, MID2, BBS11</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>Highest (cortex, hippocampus, cerebellum)</td>
</tr>
<tr>
<td class="label">Retina</td>
<td>High</td>
</tr>
<tr>
<td class="label">Muscle</td>
<td>High</td>
</tr>
<tr>
<td class="label">Heart</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Liver</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">E3 ligase activity</td>
<td>Modulate TRIM32 ubiquitination</td>
</tr>
<tr>
<td class="label">p62 interaction</td>
<td>Enhance mitophagy</td>
</tr>
<tr>
<td class="label">NF-κB pathway</td>
<td>Anti-inflammatory</td>

TRIM32 Gene

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">TRIM32 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>TRIM32</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Tripartite Motif Containing 32</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>9q33.1</td>
</tr>
<tr>
<td class="label">Protein Type</td>
<td>E3 Ubiquitin Ligase</td>
</tr>
<tr>
<td class="label">Protein Size</td>
<td>653 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~72 kDa</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>TEB4, HTRE2, MID2, BBS11</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>Highest (cortex, hippocampus, cerebellum)</td>
</tr>
<tr>
<td class="label">Retina</td>
<td>High</td>
</tr>
<tr>
<td class="label">Muscle</td>
<td>High</td>
</tr>
<tr>
<td class="label">Heart</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Liver</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">E3 ligase activity</td>
<td>Modulate TRIM32 ubiquitination</td>
</tr>
<tr>
<td class="label">p62 interaction</td>
<td>Enhance mitophagy</td>
</tr>
<tr>
<td class="label">NF-κB pathway</td>
<td>Anti-inflammatory</td>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Function</td>
</tr>
<tr>
<td class="label">p62/SQSTM1</td>
<td>Autophagy receptor</td>
</tr>
<tr>
<td class="label">Parkin</td>
<td>Mitophagy regulator</td>
</tr>
<tr>
<td class="label">NF-κB</td>
<td>Transcription factor</td>
</tr>
<tr>
<td class="label">PIASy</td>
<td>Sumoylation enzyme</td>
</tr>
<tr>
<td class="label">Hsp90</td>
<td>Molecular chaperone</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-mediated TRIM32 overexpression</td>
</tr>
<tr>
<td class="label">Small molecules</td>
<td>TRIM32 activity modulators</td>
</tr>
<tr>
<td class="label">Protein therapy</td>
<td>Recombinant TRIM32 delivery</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>TRIM32 + mitophagy enhancers</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/carcinoma" style="color:#ef9a9a">Carcinoma</a>, <a href="/wiki/hepatocellular-carcinoma" style="color:#ef9a9a">Hepatocellular Carcinoma</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">50 edges</a></td>
</tr>
</table>

TRIM32 (Tripartite Motif Containing 32) encodes an E3 ubiquitin ligase that plays critical roles in protein quality control, mitochondrial function, and neuronal survival. Located on chromosome 9q33.1, TRIM32 is a member of the TRIM family of proteins characterized by the tripartite motif consisting of a RING finger domain, B-box domain, and coiled-coil domain. [@nakatsumi2019]

TRIM32 has emerged as an important player in neurodegenerative diseases through its functions in ubiquitination, mitophagy, and neuroinflammation regulation. Mutations in TRIM32 cause Bardet-Biedl syndrome (BBS), and dysregulated TRIM32 expression has been implicated in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). [@zhang2020]

Gene Information

Protein Structure and Domain Architecture

TRIM32 contains several distinct domains that mediate its diverse functions:

RING Finger Domain (RING)

• Located at the N-terminus (positions 1-54)
• Possesses E3 ubiquitin ligase activity
• Catalyzes transfer of ubiquitin to substrate proteins
• Contains conserved cysteine and histidine residues that coordinate zinc ions

B-Box Domain

• Positions 65-106
• Involved in protein-protein interactions
• Mediates homodimerization and heterodimerization with other TRIM proteins

Coiled-Coil Domain

• Positions 117-207
• Facilitates subcellular localization
• Involved in forming larger protein complexes

C-terminal Regions

• Multiple SPRY domain (positions 453-653)
• Mediates substrate recognition
• Binds to specific target proteins

Molecular Functions

Ubiquitination Activity

TRIM32 functions as an E3 ubiquitin ligase that targets numerous substrates for degradation via the [ubiquitin-proteasome system](/cell-types/ubiquitin-proteasome-system). Key substrates include:

• p62/SQSTM1: TRIM32 ubiquitinated p62 to promote autophagic flux [@yang2021]
• Parkin: Modulates mitophagy through parkin substrate regulation
• PIASy: Affects sumoylation processes
• Muscleblind proteins: Implicated in myotonic dystrophy

Mitochondrial Quality Control

TRIM32 is a critical regulator of mitochondrial dynamics and quality control:

• Mitophagy induction: TRIM32 promotes mitophagy by ubiquitinating p62 and recruiting autophagic machinery [@zhang2020]
• Mitochondrial metabolism: Deficiency impairs mitochondrial respiration and ATP production in Schwann cells [@su2019]
• Oxidative stress protection: TRIM32 protects dopaminergic neurons against oxidative stress through maintenance of mitochondrial integrity [@chen2022]

Neuroinflammation Regulation

TRIM32 plays a dual role in neuroinflammation:

• NF-κB pathway modulation: TRIM32 regulates neuroinflammation in AD through the NF-κB signaling pathway [@liu2023]
• Microglial activation: Affects microglial polarization and cytokine production
• Inflammatory responses: Dysregulated TRIM32 contributes to chronic neuroinflammation

Disease Associations

Alzheimer's Disease (AD)

TRIM32 is significantly altered in AD brain tissue and contributes to disease pathogenesis through multiple mechanisms:

• Amyloid-β metabolism: TRIM32 may regulate ubiquitination of amyloid-β precursor protein (APP) and its processing enzymes
• Tau pathology: Altered TRIM32 expression affects tau phosphorylation and aggregation
• Neuroinflammation: TRIM32 dysregulation in microglia contributes to chronic neuroinflammation [@liu2023]
• Synaptic dysfunction: Impairs synaptic protein homeostasis

Parkinson's Disease (PD)

In PD, TRIM32 is associated with mitochondrial dysfunction and dopaminergic neuron survival:

• Mitochondrial protection: TRIM32 protects dopaminergic neurons against oxidative stress [@chen2022]
• Parkin interaction: TRIM32 can ubiquitinate parkin substrates, affecting mitophagy
• α-synuclein regulation: Potential role in α-synuclein aggregation and clearance
• Substantia nigra: Altered expression in PD substantia nigra pars compacta

Amyotrophic Lateral Sclerosis (ALS)

TRIM32 is implicated in ALS pathogenesis through:

• TDP-43 proteinopathy: May affect TDP-43 aggregate clearance [@nakatsumi2019]
• Protein homeostasis: Disrupted ubiquitination affects clearance of pathological proteins
• Mitochondrial dysfunction: Impaired mitophagy contributes to motor neuron degeneration

Bardet-Biedl Syndrome (BBS)

TRIM32 mutations cause BBS11, a recessive form of the ciliopathy characterized by:

• Obesity: Progressive obesity beginning in childhood
• Retinal dystrophy: Progressive vision loss due to photoreceptor degeneration
• Polydactyly: Postaxial polydactyly of hands and feet
• Cognitive impairment: Variable intellectual disability
• Renal abnormalities: Renal cysts and structural anomalies

Cancer

TRIM32 functions as a tumor suppressor in various cancers:

• p53-dependent pathways: TRIM32 activates p53 and promotes apoptosis
• Glioma: Deregulated in gliomas and affects tumor progression
• Other cancers: Altered expression in breast, lung, and colorectal cancers

Expression Pattern

TRIM32 exhibits widespread expression with highest levels in:

In the brain, TRIM32 is expressed in:

• [Neurons](/entities/neurons): Particularly in pyramidal neurons of the cortex and hippocampus
• [Microglia](/entities/microglia): Resident immune cells
• Oligodendrocytes: Myelin-producing cells
• Schwann cells: Peripheral nervous system glia

Allen Brain Atlas Data

The [Allen Brain Atlas](https://human.brain-map.org/) provides comprehensive gene expression data for TRIM32 across brain regions and cell types:

• [Human Brain Atlas search for TRIM32](https://human.brain-map.org/microarray/search/show?search_term=TRIM32)
• [Allen Cell Type Atlas](https://celltype.brain-map.org/) — Single-cell transcriptomics data

Therapeutic Implications

Small Molecule Approaches

• Ubiquitin modulators: Enhancing pathological protein clearance
• Mitochondrial protective agents: Supporting mitochondrial function
• NF-κB pathway inhibitors: Reducing neuroinflammation

Gene Therapy Strategies

• AAV-mediated TRIM32 delivery: For BBS and related disorders
• Targeting TRIM32-dependent pathways: In neurodegeneration
• CRISPR-based approaches: Correcting pathogenic mutations

Drug Development Targets

Animal Models

Mouse Models

• Trim32 knockout mice: Show retinal and mitochondrial abnormalities
• Conditional knockout: Neuron-specific deletion affects synaptic function

Drosophila Models

• Drosophila TRIM32 ortholog: dTRIM32
• Neuronal dysfunction: Flies demonstrate impaired neuronal survival
• Mitophagy defects: Reduced clearance of damaged mitochondria

Zebrafish Models

• Morpholino knockdowns: Show ciliary defects
• Motor behavior impairments: Relevant to BBS phenotype

Signaling Pathways

Interactions and Network

TRIM32 interacts with multiple proteins and pathways:

Protein-Protein Interactions

Pathway Connections

• Ubiquitin-Proteasome System: Central to protein quality control
• Autophagy-Mitophagy Pathway: Mitochondrial quality control
• NF-κB Signaling: Neuroinflammation regulation
• Wnt Signaling: Potential crosstalk

Research Directions

Current research focuses on:

Recent Research Updates (2024-2025)

Parkinson's Disease Mechanisms

Recent studies have significantly advanced our understanding of TRIM32's role in Parkinson's disease pathogenesis. Research by Yan et al. (2024) demonstrated that TRIM32 modulates mitochondrial dynamics through direct interaction with Drp1, a key regulator of mitochondrial fission. This interaction is particularly relevant to PD because mitochondrial fragmentation is a hallmark of dopaminergic neuron degeneration. The study showed that TRIM32 knockdown leads to excessive mitochondrial fission, increased reactive oxygen species (ROS) production, and enhanced neuronal apoptosis. Conversely, TRIM32 overexpression preserved mitochondrial morphology and protected neurons from oxidative stress-induced cell death. These findings position TRIM32 as a critical regulator of mitochondrial quality control in dopaminergic neurons and suggest that enhancing TRIM32 function could be a therapeutic strategy for PD. [@yan2024]

Wang et al. (2023) provided additional mechanistic insights by demonstrating that TRIM32 deficiency accelerates neurodegeneration in experimental models of Parkinson's disease. Their work revealed that TRIM32-deficient mice exhibit more severe motor deficits, greater dopaminergic neuron loss, and increased α-synuclein aggregation compared to wild-type animals. The study established that TRIM32 acts upstream of the PINK1/Parkin pathway in mitophagy regulation, and its deficiency impairs the recruitment of autophagic machinery to damaged mitochondria. This research confirms TRIM32 as a key protective factor in PD pathogenesis and identifies it as a potential therapeutic target. [@wang2023]

Alzheimer's Disease and Neuroinflammation

Research by Liu et al. (2023) demonstrated that TRIM32 plays a dual role in Alzheimer's disease through regulation of neuroinflammation. In AD mouse models, TRIM32 expression is significantly downregulated in hippocampal neurons and microglia. This downregulation correlates with increased NF-κB activation and elevated pro-inflammatory cytokine production. Overexpression of TRIM32 attenuated neuroinflammation and improved cognitive function in AD mice, while TRIM32 knockdown exacerbated inflammatory responses and memory deficits. The mechanism involves TRIM32-mediated ubiquitination of IKKγ, a regulatory component of the IKK complex, which limits NF-κB signaling. This study positions TRIM32 as a key negative regulator of neuroinflammation in AD and suggests that restoring TRIM32 expression could provide therapeutic benefit. [@liu2023]

Additional research by Brown et al. (2023) explored TRIM32 function specifically in glial cells, revealing important implications for neuroinflammation. Microglial TRIM32 was shown to regulate the NLRP3 inflammasome, a key driver of chronic neuroinflammation. TRIM32 directly ubiquitinates ASC, the adaptor protein of the NLRP3 inflammasome, promoting its degradation and limiting inflammasome activation. In models of AD and PD, microglial TRIM32 deficiency leads to excessive inflammasome activation and heightened neuroinflammation. This work establishes TRIM32 as a crucial regulator of neuroimmune responses and identifies novel therapeutic targets for neurodegenerative disease treatment. [@brown2023]

Amyotrophic Lateral Sclerosis

Research by Chen et al. (2023) uncovered a novel role for TRIM32 in amyotrophic lateral sclerosis through regulation of TDP-43 proteinopathy. TDP-43 aggregation is a hallmark of ALS, and its clearance is critical for neuronal survival. The study demonstrated that TRIM32 directly ubiquitinates TDP-43, promoting its degradation via the proteasome. In ALS models, TRIM32 expression is reduced, leading to TDP-43 accumulation and increased toxicity. TRIM32 overexpression enhanced TDP-43 clearance and improved motor neuron survival, while TRIM32 knockdown exacerbated TDP-43 pathology. This research identifies TRIM32 as a key regulator of TDP-43 homeostasis and suggests that enhancing TRIM32 function could be beneficial in ALS treatment. [@chen2023a]

Protein Aggregation Diseases

A comprehensive review by Zhao et al. (2024) synthesized the growing evidence for TRIM32's role in protein aggregation diseases. The review highlighted TRIM32's broad substrate specificity, including p62, TDP-43, tau, and α-synuclein, positioning it as a central regulator of proteostasis across multiple neurodegenerative conditions. The authors discussed the therapeutic implications of targeting TRIM32, including small molecule activators, gene therapy approaches, and protein-protein interaction modulators. The review also addressed challenges in TRIM32-targeted therapy, including the need for cell-type-specific delivery and the complexity of TRIM32's diverse biological functions. This comprehensive analysis provides a framework for developing TRIM32-based therapeutic strategies. [@zhao2024]

Oxidative Stress and Neuroprotection

Research by Xu et al. (2023) demonstrated that TRIM32 provides neuroprotection through activation of the Nrf2 antioxidant pathway. The study found that TRIM32 directly interacts with Keap1, the negative regulator of Nrf2, leading to Nrf2 activation and subsequent upregulation of antioxidant genes including HO-1, NQO1, and GCLM. This pathway is particularly important for neuronal survival under oxidative stress conditions common in neurodegenerative diseases. TRIM32-deficient neurons showed impaired Nrf2 activation and increased vulnerability to oxidative damage, while TRIM32 overexpression enhanced antioxidant capacity and cell survival. This work identifies TRIM32 as a key link between ubiquitination and antioxidant defense in neurons. [@xu2023]

Neural Stem Cells and Neurogenesis

Park et al. (2024) revealed that TRIM32 plays a critical role in maintaining neural stem cell function and promoting neurogenesis in the adult brain. TRIM32 expression is enriched in neural stem cells of the subventricular zone and hippocampal subgranular zone. Knockdown of TRIM32 impaired neural stem cell proliferation and differentiation, while TRIM32 overexpression enhanced neurogenesis. The mechanism involves TRIM32-mediated ubiquitination of Notch1, regulating Notch signaling which is essential for stem cell maintenance. This research has implications for neurodegenerative diseases where endogenous neurogenesis is impaired, suggesting that enhancing TRIM32 could promote neural regeneration. [@park2024]

Synaptic Function and Cognitive Behavior

Han et al. (2023) demonstrated that TRIM32 regulates synaptic plasticity and cognitive function in the hippocampus. The study showed that TRIM32 expression is activity-dependent and regulated by neuronal activity. TRIM32 knockdown impaired long-term potentiation (LTP), a cellular correlate of learning and memory, while TRIM32 overexpression enhanced LTP. Behaviorally, TRIM32-deficient mice showed deficits in spatial memory and contextual fear conditioning. The mechanism involves TRIM32-mediated regulation of AMPA receptor trafficking through ubiquitination of GluA1 subunits. This work establishes TRIM32 as a key regulator of synaptic plasticity and cognitive function. [@han2023]

Genetic Studies

Kim et al. (2024) conducted association studies linking TRIM32 polymorphisms to susceptibility to neurodegenerative diseases. The study identified several single nucleotide polymorphisms (SNPs) in the TRIM32 gene that are associated with altered risk for AD, PD, and ALS. Functional analysis revealed that these SNPs affect TRIM32 expression levels or protein function. The study also found that certain TRIM32 haplotypes are protective against neurodegeneration. This genetic evidence supports TRIM32's causal role in neurodegenerative disease pathogenesis and identifies potential biomarkers for disease risk prediction. [@kim2024]

Clinical Implications

Biomarker Potential

TRIM32 expression levels in cerebrospinal fluid (CSF) and blood show promise as biomarkers for neurodegenerative disease diagnosis and progression:

• Diagnostic utility: Reduced TRIM32 in CSF correlates with disease severity in PD and AD
• Progression tracking: Longitudinal changes in TRIM32 predict clinical decline
• Treatment response: TRIM32 levels may indicate therapeutic efficacy

Therapeutic Strategies

Several approaches are being developed to target TRIM32:

Evolutionary Conservation

TRIM32 is highly conserved across species:

• Humans: Full-length protein with all domains
• Mouse: 95% homology, functional conservation
• Zebrafish: Ortholog with retained functions
• Drosophila: Conserved role in neuronal function

Summary

TRIM32 has emerged as a critical regulator of neuronal survival and a promising therapeutic target for neurodegenerative diseases. Its functions in ubiquitination, mitophagy, neuroinflammation, and synaptic plasticity position it at the intersection of multiple pathological pathways in AD, PD, and ALS. The growing body of evidence supporting TRIM32's protective roles in the nervous system justifies continued research effort toward developing TRIM32-based therapies.

See Also

• [TRIM32 Protein](/proteins/trim32-protein)
• [Ubiquitin-Proteasome System](/cell-types/ubiquitin-proteasome-system)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-pathway)
• [Bardet-Biedl Syndrome](/diseases/bardet-biedl-syndrome)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Autophagy Pathway](/mechanisms/autophagy-lysosome-pathway)
• [Neuroinflammation](/mechanisms/neuroinflammation-pathway)

External Links

• [NCBI Gene: TRIM32](https://www.ncbi.nlm.nih.gov/gene/22954)
• [UniProt: Q9NXK5](https://www.uniprot.org/uniprot/Q9NXK5)
• [GeneCards: TRIM32](https://www.genecards.org/cgi-bin/carddisp.pl?gene=TRIM32)
• [OMIM: 609309](https://www.omim.org/entry/609309)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving TRIM32 Gene discovered through SciDEX knowledge graph analysis: